The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection. Here, Noy-Porat, Makdasi et al. report the isolation of a panel of neutralizing mAbs selected against SARS-CoV-2 receptor-binding domain (RBD) from a phage display library constructed based on patient samples collected in the acute phase of the disease, which show efficient neutralizing activities against authentic virus in vitro.
【저자키워드】 viral infection, Immunotherapy, 【초록키워드】 neutralizing antibody, SARS-CoV-2, therapy, antibody, SARS-COV-2 infection, COVID-19 pandemic, in vitro, virus, coronavirus SARS-CoV-2, Receptor binding domain, lymphocyte, Neutralizing activity, RBD, Human monoclonal antibody, Patient, Isolation, Neutralizing, epitope, neutralizing monoclonal antibody, binding, mAb, acute phase, domain, human ACE2 receptor, viral spike, inhibitory activity, selected, shown, described, collected, the disease, approved, recognize, the RBD, subset, the antibody, the SARS-CoV-2, therapeutic drug, 【제목키워드】 Neutralizing, SARS-CoV-2 spike, mAb, multiple epitope,